Teplizumab Preserves Beta-Cell Function, Modestly Improves Metabolic Control in Stage 3 Type 1 Diabetes
Background
After diagnosis of stage 3 Type 1 Diabetes (T1D), pancreatic β-cell decline persists, leading to metabolic fluctuations and acute risks despite intensive insulin therapy. Current treatments primarily manage symptoms, failing to halt the underlying autoimmune destruction. Teplizumab, an anti-CD3 monoclonal antibody, has shown promise in delaying T1D progression by modulating T-cell activity, but individual trial findings have been inconsistent. This systematic review and meta-analysis aimed to consolidate the evidence on teplizumab's efficacy and safety in this critical patient population.
Study Design
Researchers conducted a systematic review and meta-analysis of five double-blind, placebo-controlled randomized controlled trials (RCTs) involving 975 patients with stage 3 Type 1 Diabetes. They searched PubMed, Embase, Cochrane Library, and Web of Science up to October 31, 2025, for parallel RCTs comparing intravenous teplizumab monotherapy with placebo or standard care. The primary outcome assessed was the preservation of MMTT C-peptide AUC at 9-15 months, with a secondary assessment at 18-24 months. Other secondary outcomes included insulin dose, HbA1c, and partial remission rate (defined by IDAA1c≤9). Risk of bias was evaluated using RoB 2, and random-effects meta-analysis was performed, including subgroup, sensitivity, and GRADE assessments.
Results
Teplizumab significantly improved C-peptide AUC preservation at 9-15 months (SMD=0.28, 95% CI 0.09-0.48, P=0.016), exceeding the minimal clinically important difference of 0.20. While a favorable trend was observed at 18-24 months (SMD=0.27, 95% CI -0.02-0.56), it did not reach statistical significance.
Teplizumab reduced daily insulin dose by 0.11 U/kg/day (MD=-0.11 U/kg/day) and lowered
HbA1cby 0.22% (MD=-0.22%), while increasing the partial remission rate by 39% (RR=1.39). Regarding safety, immune-related adverse events were more frequent, with lymphopenia increasing 3.36-fold (RR=3.36) and infusion-related reactions 2.79-fold (RR=2.79). However, infection rates (RR=0.98) and diabetic ketoacidosis (RR=0.80) showed no significant difference, and severe hypoglycemia decreased by 33% (RR=0.67). TheGRADEassessment indicated moderate certainty for short-term outcomes but low certainty for long-termC-peptidepreservation and some acute events.
Key Findings
- Teplizumab preserved
C-peptide AUCat 9-15 months (SMD=0.28, P=0.016), exceeding the MCID. - Daily insulin dose was reduced by 0.11 U/kg/day and
HbA1cby 0.22% with teplizumab. - Partial remission rates increased by 39% (RR=1.39) in teplizumab-treated patients.
- Immune-related adverse events like lymphopenia (RR=3.36) and infusion reactions (RR=2.79) were more common.
- Severe hypoglycemia decreased by 33% (RR=0.67), with no difference in infection or DKA rates.
Why It Matters
This meta-analysis provides strong evidence that teplizumab can preserve β-cell function and offer modest metabolic benefits in stage 3 Type 1 Diabetes, reinforcing its role as a disease-modifying therapy. For individuals with newly diagnosed T1D, this suggests a potential to extend the 'honeymoon phase' and reduce the burden of intensive insulin management. While the short-term benefits are clear, the lower certainty for long-term C-peptide preservation highlights the need for continued monitoring and research into sustained efficacy. Clinicians and patients must weigh these benefits against the increased risk of immune-related adverse events, particularly lymphopenia and infusion reactions. This data supports teplizumab's current clinical use and informs future protocols aiming to optimize T1D management, potentially by combining it with other agents like GLP-1RAs, as explored in ongoing trials.
teplizumab
type-1-diabetes
beta-cell-preservation
immunotherapy
meta-analysis
rct